Drug Type Biosimilar, Hormone |
Synonyms Follitropin Alfa Biosimilar (Qilu Pharmaceutical Co., Ltd.), 重组人促卵泡激素α生物类似药(齐鲁制药有限公司), QL-1012 + [2] |
Target |
Mechanism FSHR agonists(Follicle-stimulating hormone receptor agonists) |
Therapeutic Areas |
Active Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date CN (17 Dec 2021), |
Regulation- |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Infertility, Female | CN | 17 Dec 2021 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Ovarian Hyperstimulation Syndrome | Phase 3 | CN | 31 Oct 2018 | |
Follicle stimulating hormone deficiency | Phase 1 | CN | 05 Feb 2025 | |
Female infertility associated with anovulation | Phase 1 | CN | 17 Aug 2017 | |
Anovulation | IND Approval | CN | 09 Jan 2025 | |
Luteinizing hormone deficiency | IND Approval | CN | 09 Jan 2025 | |
Polycystic Ovary Syndrome | IND Approval | CN | 09 Jan 2025 |